{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:17:50Z","timestamp":1773260270105,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.maturitas.2011.11.018","type":"journal-article","created":{"date-parts":[[2011,12,22]],"date-time":"2011-12-22T10:13:45Z","timestamp":1324548825000},"page":"221-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis"],"prefix":"10.1016","volume":"71","author":[{"given":"Barry S.","family":"Komm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkadi A.","family":"Chines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2011.11.018_bib0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000063449","article-title":"Epidemiology of osteoporotic fractures","volume":"54","author":"Dennison","year":"2000","journal-title":"Horm Res"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0010","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1210\/jc.2007-1876","article-title":"Bone mineral density changes during the menopause transition in a multiethnic cohort of women","volume":"93","author":"Finkelstein","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0015","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","article-title":"Requirements for DXA for the management of osteoporosis in Europe","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0030","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators \u2013 mechanisms of action and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/gme.0b013e3181906fa3","article-title":"Designing the ideal selective estrogen receptor modulator \u2013 an achievable goal?","volume":"16","author":"Taylor","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0045","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0055","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2011.11.018_bib0060","article-title":"Assessment of the effect of bazedoxifene on non-vertebral fracture risk","volume":"24","author":"McCloskey","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2474-11-130","article-title":"Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis","volume":"11","author":"Christiansen","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0070","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/gme.0b013e3181a816be","article-title":"Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0075","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","article-title":"Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women","volume":"16","author":"Archer","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0080","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/gme.0b013e3181a7fb1e","article-title":"The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis","volume":"16","author":"Harvey","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0085","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","article-title":"Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial","volume":"22","author":"de Villiers","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0090","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","author":"Silverman","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0095","series-title":"Presented at the 13th International Menopause Society World Congress on Menopause","article-title":"Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study","author":"Palacios","year":"2011"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0100","first-page":"1344","article-title":"Reproductive safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study","volume":"18","author":"Palacios","year":"2011","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1258\/mi.2010.010033","article-title":"Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex","volume":"16","author":"Pickar","year":"2010","journal-title":"Menopause Int"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0110","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0115","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0120","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2009.05.094","article-title":"Endometrial effects of a tissue selective estrogen complex containing bazedoxifene\/conjugated estrogens as a menopausal therapy","volume":"92","author":"Pickar","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0125","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.fertnstert.2009.05.093","article-title":"Bazedoxifene\/conjugated estrogens (BZA\/CE): incidence of uterine bleeding in postmenopausal women","volume":"92","author":"Archer","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0135","first-page":"S97","article-title":"Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD","volume":"20","author":"McClung","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0140","first-page":"S173","article-title":"Extraskeletal effects of lasofoxifene on postmenopausal women","volume":"20","author":"Davidson","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0145","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0150","unstructured":"Pfizer Inc. FABLYN\u00ae (lasofoxifene tartrate) 0.5mg Tablets. NDA 22-242. Reproductive Health Drugs Advisory Committee Briefing Document, 08 September 2008. http:\/\/www.fdagov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4381b1-02-Pfizer.pdf; 2008."},{"key":"10.1016\/j.maturitas.2011.11.018_bib0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/gme.0b013e3181e84bb4","article-title":"Postmenopausal evaluation and risk reduction with lasofoxifene trial: 5-year gynecological outcomes","volume":"18","author":"Goldstein","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0160","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00198-009-1060-5","article-title":"Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass","volume":"21","author":"Downs","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0165","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2008-2143","article-title":"Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass","volume":"94","author":"Bolognese","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0170","article-title":"Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women","author":"Cummings","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0175","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0180","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09513590410001672197","article-title":"Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women","volume":"18","author":"Komi","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0185","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","article-title":"Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women","volume":"24","author":"Komi","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0190","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0195","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women","volume":"12","author":"Komi","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0200","series-title":"Abstract presented at the 89th Annual Meeting of the Endocrine Society","article-title":"RAD-1901, a novel SERM, has efficacy in an animal model of vasomotor symptoms","author":"Hattersley","year":"2007"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0960-0760(01)00139-X","article-title":"EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium","volume":"79","author":"Labrie","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jsbmb.2004.05.009","article-title":"The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats","volume":"92","author":"Goss","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.maturitas.2011.11.018_bib0215","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1021\/jm0509795","article-title":"A selective estrogen receptor modulator for the treatment of hot flushes","volume":"49","author":"Wallace","year":"2006","journal-title":"J Med Chem"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512211004038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512211004038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:54:09Z","timestamp":1759913649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512211004038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0378512211004038"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2011.11.018","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2011.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}